David R. Liu notes new China rules that can allow therapies proven in investigator-initiated trials to be given as treatments without national regulatory approval, potentially accelerating clinical deployment compared with US/EU models.
New rules spur cell and gene therapy trials in China
Once proven safe and effective in investigator-initiated trials, therapies [in China] can then be given to patients as treatments, again without requiring national regulatory approval.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new expert voices, debates, and emerging ideas.
← Back to Healthcare